Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/S1474-4422(17)30280-6 http://scihub22266oqcxt.onion/10.1016/S1474-4422(17)30280-6 C5604739!5604739!28920889     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Lancet+Neurol 2017 ; 16 (10): 837-47 Nephropedia Template TP {{tp|p=28920889|t=2017. Therapies targeting DNA and RNA in Huntington s disease |pdf=|usr=}}{{28920889}} gab.com Text Therapies targeting DNA and RNA in Huntington s disease JO: Lancet Neurol http://www.kidney.de/pget.php?&tw=1&pmid=28920889 #FOAvip No disease-slowing treatments exist for Huntington?s disease (HD), but its monogenic inheritance makes it an appealing candidate for the development of therapeutics targeting pathogenic processes close to its root genetic cause. HD is caused by CAG repeat expansions in the HTT gene, which encodes huntingtin protein; targeting of HTT transcription and the translation of its mRNA are therefore an area of intense investigation. ?Huntingtin-lowering? strategies include antisense oligonucleotides (ASOs) and RNA interference compounds targeting mRNA; and zinc-finger transcriptional repressors (ZFTR) and newer CRISPR/Cas9 methods aiming to reduce transcription by targeting DNA. An intrathecally-delivered ASO targeting total huntingtin is now well into its first human clinical trial, with other ASO approaches expected to enter trials within the next 1-2 years, and virally-delivered RNAi and ZFTR in advanced testing in animal models. Meanwhile, recent advances to improve the design and delivery of targeted therapeutics are likely to improve their efficacy, safety, tolerability and duration of effect. Twit Text FOAVip Therapies targeting DNA and RNA in Huntington s disease ????Lancet Neurol http://www.kidney.de/pget.php?&tw=1&pmid=28920889 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=28920889 #FOAvip English Wikipedia <ref>{{Cite pmid|28920889}}</ref> Therapies targeting DNA and RNA in Huntington s disease #MMPMID28920889 Wild EJ; Tabrizi S Lancet Neurol 2017[Oct]; 16 (10): 837-47 PMID28920889show ga No disease-slowing treatments exist for Huntington?s disease (HD), but its monogenic inheritance makes it an appealing candidate for the development of therapeutics targeting pathogenic processes close to its root genetic cause. HD is caused by CAG repeat expansions in the HTT gene, which encodes huntingtin protein; targeting of HTT transcription and the translation of its mRNA are therefore an area of intense investigation. ?Huntingtin-lowering? strategies include antisense oligonucleotides (ASOs) and RNA interference compounds targeting mRNA; and zinc-finger transcriptional repressors (ZFTR) and newer CRISPR/Cas9 methods aiming to reduce transcription by targeting DNA. An intrathecally-delivered ASO targeting total huntingtin is now well into its first human clinical trial, with other ASO approaches expected to enter trials within the next 1-2 years, and virally-delivered RNAi and ZFTR in advanced testing in animal models. Meanwhile, recent advances to improve the design and delivery of targeted therapeutics are likely to improve their efficacy, safety, tolerability and duration of effect. äTherapies targeting DNA and RNA in Huntington s disease (epmc).pdf DeepDyve Pubget Overpricing